Virus News and Research

Latest Virus News and Research

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

9 Jan 2010

CDC encourages public to receive H1N1 vaccine; PBS examines arrival of vaccine in developing countries

During a media briefing Thursday, Anne Schuchat, director of the National Center for Immunization and Respiratory Diseases at the CDC, warned against complacency over the H1N1 (swine flu), and encouraged Americans who had not yet received the H1N1 vaccine to do so, CNN reports.

8 Jan 2010

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Lessons learned from the first 13 children at Johns Hopkins Children's Center to become critically ill from the H1N1 virus show that although all patients survived, serious complications developed quickly, unpredictably, with great variations from patient to patient and with serious need for vigilant monitoring and quick treatment adjustments.

8 Jan 2010

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50 million. Scientists and clinicians at The University of Texas Health Science Center at Houston can address the diagnosis and treatment of these conditions, as well as the latest advances in research.

8 Jan 2010

Business leaders should continue to monitor H1N1 risk management to alleviate major impact on costs and revenues

The swine flu pandemic may be off the media’s radar screen, but business executives can ill afford to rest easy. Experts from the National Center for Critical Incident Analysis (NCCIA), who have studied how to respond to pandemics and bioterrorism attacks, warn that executives need to continue to monitor and manage unknown risk factors that might cause the flu to have a major impact upon costs and revenues.

8 Jan 2010

Researchers discover rules that dictate the three-dimensional shapes of RNA molecules

University of Michigan researchers have discovered the rules that dictate the three-dimensional shapes of RNA molecules, rules that are based not on complex chemical interactions but simply on geometry.

8 Jan 2010

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Cell Medica, a clinical cellular therapeutics company developing proven cell therapies which address important unmet clinical needs in oncology and infectious diseases, announced today the signing of an R&D agreement with the Center for Cell and Gene Therapy, a joint program of Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital, Houston, Texas.

8 Jan 2010

Frequent chlamydia screening does not reduce infection in teenage girls

Frequent testing and treatment of infection does not reduce the prevalence of chlamydia in urban teenage girls, according to a long term study by Indiana University School of Medicine researchers published in the January 1, 2010 issue of the Journal of Infectious Diseases.

8 Jan 2010

H1N1 can spread during commercial flights; avoid economy and fly first class, UCLA researchers say

Viruses love plane travel. They get to fly around the world inside a closed container while their infected carrier breathes and coughs, spreading pathogens to other passengers, either by direct contact or through the air. And once people deplane, the virus can spread to other geographical areas.

8 Jan 2010

ZymoGenetics announces pricing of public offering of 14,000,000 shares

ZymoGenetics, Inc. today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000.

8 Jan 2010

Initiation of double blind placebo controlled multi-center trial of DAS181 announced

NexBio, Inc. announced today the initiation of a double blind placebo controlled multi-center trial in the U.S. and Mexico of DAS181 (Fludase®) for the treatment of laboratory confirmed influenza infection.

8 Jan 2010

UAB issues updated guidelines for childhood and teen immunization schedule

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

7 Jan 2010

Canada loans 5m doses of H1N1 vaccine to Mexico

Canadian Health Minister Leona Aglukkaq on Wednesday announced plans for the country to loan Mexico five million doses of the H1N1 (swine flu) vaccine, Agence France-Presse reports.

7 Jan 2010

CFIDS Association of America issues statement in response to XMRV study

The CFIDS Association of America issued the following statement in response to a study published in today’s edition of PLoS One that failed to detect the XMRV virus in banked samples drawn from 186 CFS patients in the United Kingdom. A study published Oct. 8, 2009 in Science reported that 68 of 101 CFS patients from clinics in the U.S. tested positive for XMRV.

7 Jan 2010

EPO grants notice of allowance for Response Biomedical’s ‘Fong Patent’

Response Biomedical Corporation announced today that the Company has received a Notice of Allowance from the European Patent Office for the patent entitled “Sensitive Immunochromatographic Assay”, referred to as the “Fong Patent”.

7 Jan 2010

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has received a milestone payment from its partner Roche related to initiation of pre-IND (investigational new drug application) studies for an RNAi therapeutics product candidate.

7 Jan 2010

Flu vaccine safe but ineffective for RA patients treated with rituximab

Rheumatoid arthritis (RA) patients are partially protected by the influenza vaccine 6-10 months after treatment with rituximab. Researchers determined that while the flu vaccine is safe, it is ineffective for RA patients in the first 6 months following rituximab treatment.

7 Jan 2010

Diffusion tensor imaging detects signs of Alzheimer's disease

A new type of brain scan, called diffusion tensor imaging (DTI), appears to be better at detecting whether a person with memory loss might have brain changes of Alzheimer's disease, according to a new study published in the January 6, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Canada supports Mexico's pandemic response efforts

The Honourable Leona Aglukkaq, Minister of Health, on behalf of the Government of Canada, has announced it will be providing five million doses of H1N1 flu vaccine to Mexico to help bridge that country's immediate pandemic vaccine requirements. This is not a donation. Mexico will replenish Canada's H1N1 vaccine supply by March 31, 2010.

7 Jan 2010

Virus News and Research

Latest Virus News and Research

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

CDC encourages public to receive H1N1 vaccine; PBS examines arrival of vaccine in developing countries

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Business leaders should continue to monitor H1N1 risk management to alleviate major impact on costs and revenues

Researchers discover rules that dictate the three-dimensional shapes of RNA molecules

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Frequent chlamydia screening does not reduce infection in teenage girls

H1N1 can spread during commercial flights; avoid economy and fly first class, UCLA researchers say

ZymoGenetics announces pricing of public offering of 14,000,000 shares

Initiation of double blind placebo controlled multi-center trial of DAS181 announced

UAB issues updated guidelines for childhood and teen immunization schedule

Canada loans 5m doses of H1N1 vaccine to Mexico

CFIDS Association of America issues statement in response to XMRV study

EPO grants notice of allowance for Response Biomedical’s ‘Fong Patent’

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Flu vaccine safe but ineffective for RA patients treated with rituximab

Diffusion tensor imaging detects signs of Alzheimer's disease

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Canada supports Mexico's pandemic response efforts

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in